Listar por tema "Lamivudine/therapeutic use"

Mostrando ítems 1-2 de 2

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

Hidalgo-Tenorio, Carmen; Pasquau, Juan; Vinuesa, David; Ferra, Sergio; Terron, Alberto; SanJoaquin, Isabel; Payeras, Antoni; Juan-Martínez, Onofre; López-Ruz, Miguel-Ángel; Omar, Mohamed; de-la-Torre-Lima, Javier; López-Lirola, Ana; Palomares, Jesús; Blanco, José-Ramón; Montero, Marta; García-Vallecillos, Coral (MDPI, 2022-03)

Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference ...
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, No

Llibre, Josep-M; Brites, Carlos; Cheng, Chien-Yu; Osiyemi, Olayemi; Galera, Carlos; Hocqueloux, Laurent; Maggiolo, Franco; Degen, Olaf; Taylor, Stephen; Blair, Elizabeth; Man, Choy; Wynne, Brian; Oyee, James; Underwood, Mark; Curtis, Lloyd; Bontempo, Gilda; van-Wyk, Jean (OXFORD UNIV PRESS INC, 2023-02)

BACKGROUND: In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide-based regimens in treatment-experienced adults with HIV-1. The phase 3 ...

Mostrando ítems 1-2 de 2

Buscar en DSpace